237730

Dual triggering for final oocyte maturation compared to single triggering in GnRH antagonist (IVF-ICSI) protocols (Randomized Controlled Trial)

Article

Last updated: 03 Jan 2025

Subjects

-

Tags

-

Abstract

Abstract
Background: Infertility is one of the major medical problems in the world which has led to continuous research
and advances in the field of assisted reproductive technology (ART),
Aim of the work: to investigate whether co-administration of GnRH-a and hCG for final oocyte maturation (dual
trigger) would improve number of oocytes retrieved& its
quality and eventually IVF/ICSI clinical outcomes compared to single triggers in women with normal ovarian
response undergoing (IVF/ICSI) technique using GnRH
antagonist protocol of stimulation.
Patients and Methods: A total 120 patients were included in this study, randomized and divided into two groups:
Group (1): The study group; included 60 patients who received the dual trigger. Group (2): The control group; who
included 60 patients, age matched, who received the hCG
trigger alone. All participants were subjected to proper
history taking, complete general, abdominal and pelvic
examination, and full investigations to confirm criteria
of the study. All participants were subjected to controlled
ovarian hyper stimulation protocol according to GnRH
antagonist protocol starting on day 2-3 of the menstrual
cycle with a starting daily administration of FSH, human
menopausal gonadotropin hMG, or highly purified hMG,
or highly purified FSH or with recombinant FSH (r.FSH)
intramuscularly for 4–5 days, and continued until the day
of final oocyte maturation injection.
Results: the current study showed statistically significant difference with p-value <0.05 between study groups
as regards to the number of retrieved oocytes (cases:
11.42±4.2 vs. control: 9.8±4.9), number of MII oocyte retrieved (dual trigger: 6.2±2.7 vs. single trigger: 4.6±3.1),
and number of fertilized oocyte (dual trigger: 4.03±2.2 vs.
single trigger: 3.05±2.5) with higher mean among dual
trigger group. In the current study also the dual-trigger
group demonstrated a significantly higher percentage as
regards to biochemical pregnancy rate (cases: 68.3%vs.
33.3% among controls), clinical pregnancy rate (cas-

es: 58.3% vs. 31.7% among controls) and
implantation rate (cases: 41.3% vs. 21.4%
among controls) with a statistically significant difference with p-value <0.05 between
study groups. Both groups showed no statistically significant difference as regards
to the mean number of embryos transferred
(1.9±1.01 in cases vs. 1.7±1.2 in control)
and number of frozen embryos (1.33±1.08 in
cases vs. 1.1±1.4 in control), or as regards
to complications; whether ET cancellation or
incidence of sever OHSS.
Conclusion: In conclusion, in terms of the
number of mature retrieved oocytes, implantation rate and clinical pregnancy rate in normal responders undergoing IVF/ICSI using
antagonist protocols, a dual-trigger approach
with a GnRH agonist and the standard dosage of hCG was found to be significantly superior to an hCG trigger alone.

DOI

10.21608/egyfs.2022.237730

Keywords

Key words: Dual triggering, oocyte maturation, single triggering, GnRH antagonist

Authors

First Name

Marwan

Last Name

Elkady

MiddleName

O.

Affiliation

Department of Obstetrics and Gynecology Faculty of Medicine, Ain Shams University

Email

marwan-elkady@hotmail.com

City

-

Orcid

-

Volume

26

Article Issue

2

Related Issue

34259

Issue Date

2022-05-01

Receive Date

2022-05-17

Publish Date

2022-05-01

Page Start

49

Page End

60

Print ISSN

1110-6352

Online ISSN

2536-9768

Link

https://egyfs.journals.ekb.eg/article_237730.html

Detail API

https://egyfs.journals.ekb.eg/service?article_code=237730

Order

7

Type

Original Article

Type Code

319

Publication Type

Journal

Publication Title

The Egyptian Journal of Fertility of Sterility

Publication Link

https://egyfs.journals.ekb.eg/

MainTitle

Dual triggering for final oocyte maturation compared to single triggering in GnRH antagonist (IVF-ICSI) protocols (Randomized Controlled Trial)

Details

Type

Article

Created At

22 Jan 2023